サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1533901

寄生虫病治療学の世界市場

Parasitic Diseases Therapeutics

出版日
ページ情報
英文 279 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
寄生虫病治療学の世界市場
出版日: 2024年08月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 279 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

寄生虫病治療学の世界市場は2030年までに22億米ドルに達する

2023年に17億米ドルと推定される寄生虫病治療学の世界市場は、分析期間2023-2030年にCAGR 3.3%で成長し、2030年には22億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである駆虫薬は、CAGR 3.5%を記録し、分析期間終了時には11億米ドルに達すると予測されます。抗原虫薬セグメントの成長率は、分析期間中CAGR 2.8%と推定されます。

米国市場は4億7,310万米ドルと推定、中国はCAGR6.4%で成長予測

米国の寄生虫病治療学市場は2023年に4億7,310万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億4,950万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは6.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.0％と2.5％と予測されています。欧州では、ドイツがCAGR 1.7%で成長すると予測されています。

世界の寄生虫病治療学市場- 主要動向と促進要因まとめ

原虫、蠕虫、外部寄生虫などさまざまな生物によって引き起こされる寄生虫病は、特に熱帯・亜熱帯地域において、世界的に公衆衛生上の重大な課題をもたらし続けています。マラリア、リーシュマニア症、住血吸虫症、リンパ系フィラリア症などを含むこれらの疾患は、特に小児や免疫不全者の間で、しばしば深刻な罹患率と死亡率をもたらします。寄生虫症の治療には、宿主の体内から寄生虫を排除し、症状を緩和し、感染を予防することを目的としたさまざまな治療法があります。従来の治療では、マラリアにはクロロキン、蠕虫感染症にはアルベンダゾールなどの抗寄生虫薬が用いられ、数十年にわたり治療の中心となってきました。しかし、寄生虫の薬剤耐性株の出現により、これらの病気と闘うための、より効果的な新しい治療薬の開発が必要とされています。

寄生虫病治療薬の分野における最近の動向は、新薬の発見、ワクチン開発、併用療法に焦点を当てた革新的な研究開発によって牽引されています。寄生虫の生態をより深く理解し、新たな創薬標的を発見するために、研究者たちはハイスループット・スクリーニング技術を駆使して新薬候補を同定し、ゲノミクスやプロテオミクスの進歩を活用しています。マラリア・ワクチンRTS,S/AS01のような寄生虫病に対するワクチンの開発は、感染予防と疾病負担の軽減における重要なブレークスルーとなります。さらに、治療効果を高め、薬剤耐性の発現を遅らせるために、作用機序の異なる複数の薬剤を使用する併用療法がますます活用されるようになっています。寄生虫の複雑なライフサイクルや、様々な条件下で適応し生存する能力を考えると、このような多面的なアプローチは寄生虫疾患の管理において極めて重要です。

寄生虫病治療学市場の開拓は、世界の旅行、気候変動、新興国における不十分な衛生環境などによる寄生虫感染症の流行増加など、いくつかの要因によって推進されています。診断ツールの技術的進歩により、寄生虫疾患の早期発見と正確な診断が向上し、タイムリーで効果的な治療が容易になった。消費者行動、特に疾病の蔓延率が高い地域では、利用しやすく手頃な価格の治療に対する需要が高まっています。さらに、世界保健機関（WHO）やビル・アンド・メリンダ・ゲイツ財団（Bill &Melinda Gates Foundation）などの組織による世界・ヘルス・イニシアチブと資金援助が、この分野の研究開発に大きな支援となっています。新しい抗寄生虫薬やワクチンに対する規制上の優遇措置や迅速な承認も、市場の成長に寄与しています。製薬企業が革新的な治療法への投資を継続し、新興市場への進出を拡大する中、寄生虫病治療学市場は成長が見込まれ、感染者の健康状態の改善と生活の質の向上が期待されます。

調査対象企業の例（全42件）

  • Amneal Pharmaceuticals LLC
  • Bayer AG
  • Cipla Ltd
  • GSK Plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Reese Pharmaceutical Company
  • Sanaria Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals USA, Inc.
  • Victor Medical Company
  • Zydus Pharmaceuticals（USA）Inc.
  • ;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26812

Global Parasitic Diseases Therapeutics Market to Reach US$2.2 Billion by 2030

The global market for Parasitic Diseases Therapeutics estimated at US$1.7 Billion in the year 2023, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2023-2030. Anthelmintics Drugs, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Antiprotozoals Drugs segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$473.1 Million While China is Forecast to Grow at 6.4% CAGR

The Parasitic Diseases Therapeutics market in the U.S. is estimated at US$473.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$449.5 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Parasitic Diseases Therapeutics Market - Key Trends and Drivers Summarized

Parasitic diseases, caused by various organisms such as protozoa, helminths, and ectoparasites, continue to pose significant public health challenges worldwide, particularly in tropical and subtropical regions. These diseases, including malaria, leishmaniasis, schistosomiasis, and lymphatic filariasis, often result in severe morbidity and mortality, particularly among children and immunocompromised individuals. Therapeutics for parasitic diseases involve a range of treatments designed to eliminate the parasites from the host body, alleviate symptoms, and prevent transmission. Traditional treatments have included antiparasitic drugs such as chloroquine for malaria and albendazole for helminth infections, which have been the mainstay of treatment for decades. However, the emergence of drug-resistant strains of parasites has necessitated the development of new and more effective therapeutics to combat these diseases.

Recent advancements in the field of parasitic disease therapeutics have been driven by innovative research and development efforts focusing on novel drug discovery, vaccine development, and combination therapies. Researchers are employing high-throughput screening techniques to identify new drug candidates, leveraging advances in genomics and proteomics to understand parasite biology better and discover new drug targets. The development of vaccines against parasitic diseases, such as the RTS,S/AS01 malaria vaccine, represents a significant breakthrough in preventing infection and reducing disease burden. Additionally, combination therapies, which use multiple drugs with different mechanisms of action, are being increasingly utilized to enhance treatment efficacy and delay the onset of drug resistance. This multifaceted approach is crucial in managing parasitic diseases, given the complex life cycles of parasites and their ability to adapt and survive under various conditions.

The growth in the parasitic diseases therapeutics market is driven by several factors, including the increasing prevalence of parasitic infections due to global travel, climate change, and inadequate sanitation in developing regions. Technological advancements in diagnostic tools have improved the early detection and accurate diagnosis of parasitic diseases, facilitating timely and effective treatment. Consumer behavior, particularly in regions with high disease prevalence, shows a growing demand for accessible and affordable treatments. Additionally, global health initiatives and funding from organizations such as the World Health Organization (WHO) and the Bill & Melinda Gates Foundation have provided substantial support for research and development in this field. Regulatory incentives and fast-track approvals for new antiparasitic drugs and vaccines also contribute to market growth. As pharmaceutical companies continue to invest in innovative treatments and expand their reach into emerging markets, the parasitic diseases therapeutics market is expected to grow, offering improved health outcomes and enhanced quality of life for affected populations.

Select Competitors (Total 42 Featured) -

  • Amneal Pharmaceuticals LLC
  • Bayer AG
  • Cipla Ltd
  • GSK Plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Reese Pharmaceutical Company
  • Sanaria Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals USA, Inc.
  • Victor Medical Company
  • Zydus Pharmaceuticals (USA) Inc.
  • ;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Parasitic Diseases Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Burden of Parasitic Diseases Drives Urgent Need for Effective Therapeutics
    • Breakthroughs in Molecular Biology and Parasitology Propel Drug Development
    • Expansion of Global Health Initiatives to Combat Malaria, Chagas Disease, and Others to Benefit Growth
    • Impact of Climate Change on Parasitic Disease Spread and Epidemiology
    • Governmental Funding and Policy Support for Neglected Tropical Diseases, Remain Crucial for New Drug Development
    • Development of Vaccines as a Preventative Strategy Against Parasitic Infections
    • Rising Travel and Migration Patterns Influence Disease Transmission Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Parasitic Diseases Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Parasitic Diseases Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Parasitic Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anthelmintics Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anthelmintics Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Anthelmintics Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antiprotozoals Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antiprotozoals Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antiprotozoals Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Distribution Channel Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Distribution Channel Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Distribution Channel Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • JAPAN
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • CHINA
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • EUROPE
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Parasitic Diseases Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Parasitic Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • FRANCE
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • GERMANY
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Parasitic Diseases Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Parasitic Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • INDIA
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Parasitic Diseases Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Parasitic Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Parasitic Diseases Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Parasitic Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • AFRICA
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION